Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02466386 · ClinicalTrials.gov registry record · Phase 3
Safety and Tolerability Study of SPD489 in Preschool Children Aged 4-5 Years, Diagnosed With Attention-deficit/Hyperactivity Disorder
A Phase 3 study, sponsored by Shire.
- Completed
- Registry status
- Phase 3
- Development phase
- 113
- Enrollment target
NCT02466386 is a Phase 3 study that has completed, run by Shire. The registered enrollment target is 113 participants.
The verdict
NCT02466386, a Phase 3 study, has completed, sponsored by Shire.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 113 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the long-term safety of SPD489 administered as a daily morning dose (5, 10, 15, 20, and 30 mg/day) in preschool children diagnosed with Attention-deficit/Hyperactivity Disorder (ADHD).
Interventions
- DRUG SPD489
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 113 participants |
| Start Date | 2015-08-21 |
| Est. Completion | 2020-01-03 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02466386
The ClinicalTrials.gov registry entry for NCT02466386 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 113 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Shire, which has 245 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which SPD489 is the first listed.
NCT02466386 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02466386 about?
NCT02466386 is a clinical study titled "Safety and Tolerability Study of SPD489 in Preschool Children Aged 4-5 Years, Diagnosed With Attention-deficit/Hyperactivity Disorder". The purpose of this study is to evaluate the long-term safety of SPD489 administered as a daily morning dose (5, 10, 15, 20, and 30 mg/day) in preschool children diagnosed with Attention-deficit/Hyperactivity Disorder (ADHD).
What is the current status of trial NCT02466386?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 113 participants. The study started on 2015-08-21. Estimated completion is 2020-01-03.
What interventions are being tested in trial NCT02466386?
The interventions under investigation include: SPD489 (DRUG).
Who is sponsoring clinical trial NCT02466386?
This trial is sponsored by Shire, which has 245 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.